End-of-day quote
Shanghai S.E.
06:00:00 2024-04-25 pm EDT
|
5-day change
|
1st Jan Change
|
45.61
CNY
|
+2.96%
|
|
+9.43%
|
+0.84%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
385,431
|
591,745
|
323,076
|
245,741
|
287,598
|
290,014
|
-
|
-
|
Enterprise Value (EV)
1 |
380,387
|
580,941
|
309,445
|
231,891
|
266,852
|
266,656
|
262,529
|
258,757
|
P/E ratio
|
72.9
x
|
93.7
x
|
71.4
x
|
63.2
x
|
66.5
x
|
53.3
x
|
44.4
x
|
36.4
x
|
Yield
|
0.26%
|
0.18%
|
0.32%
|
0.42%
|
0.44%
|
0.43%
|
0.49%
|
0.66%
|
Capitalization / Revenue
|
16.6
x
|
21.3
x
|
12.5
x
|
11.6
x
|
12.6
x
|
11
x
|
9.71
x
|
8.36
x
|
EV / Revenue
|
16.3
x
|
20.9
x
|
11.9
x
|
10.9
x
|
11.7
x
|
10.2
x
|
8.79
x
|
7.46
x
|
EV / EBITDA
|
56
x
|
77.6
x
|
63.6
x
|
49.2
x
|
47.1
x
|
43.9
x
|
36.3
x
|
30.1
x
|
EV / FCF
|
117
x
|
202
x
|
120
x
|
-328
x
|
43.2
x
|
72.4
x
|
49.5
x
|
37.7
x
|
FCF Yield
|
0.86%
|
0.5%
|
0.83%
|
-0.3%
|
2.32%
|
1.38%
|
2.02%
|
2.65%
|
Price to Book
|
15.6
x
|
19.5
x
|
9.27
x
|
6.5
x
|
7.13
x
|
6.53
x
|
5.75
x
|
5.22
x
|
Nbr of stocks (in thousands)
|
6,341,638
|
6,370,846
|
6,371,045
|
6,377,915
|
6,358,560
|
6,358,560
|
-
|
-
|
Reference price
2 |
60.78
|
92.88
|
50.71
|
38.53
|
45.23
|
45.61
|
45.61
|
45.61
|
Announcement Date
|
3/22/20
|
4/19/21
|
4/22/22
|
4/21/23
|
4/17/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
23,289
|
27,735
|
25,906
|
21,275
|
22,820
|
26,261
|
29,865
|
34,697
|
EBITDA
1 |
6,796
|
7,483
|
4,868
|
4,717
|
5,666
|
6,068
|
7,234
|
8,590
|
EBIT
1 |
6,150
|
7,007
|
4,665
|
4,112
|
4,910
|
5,643
|
6,906
|
8,464
|
Operating Margin
|
26.41%
|
25.26%
|
18.01%
|
19.33%
|
21.52%
|
21.49%
|
23.12%
|
24.39%
|
Earnings before Tax (EBT)
1 |
6,056
|
6,895
|
4,466
|
3,968
|
4,667
|
5,825
|
7,106
|
8,785
|
Net income
1 |
5,328
|
6,328
|
4,530
|
3,906
|
4,302
|
5,384
|
6,428
|
7,724
|
Net margin
|
22.88%
|
22.82%
|
17.49%
|
18.36%
|
18.85%
|
20.5%
|
21.52%
|
22.26%
|
EPS
2 |
0.8333
|
0.9917
|
0.7100
|
0.6100
|
0.6800
|
0.8561
|
1.028
|
1.254
|
Free Cash Flow
1 |
3,257
|
2,881
|
2,570
|
-706.7
|
6,180
|
3,681
|
5,305
|
6,866
|
FCF margin
|
13.98%
|
10.39%
|
9.92%
|
-3.32%
|
27.08%
|
14.02%
|
17.76%
|
19.79%
|
FCF Conversion (EBITDA)
|
47.92%
|
38.5%
|
52.8%
|
-
|
109.08%
|
60.65%
|
73.33%
|
79.92%
|
FCF Conversion (Net income)
|
61.12%
|
45.53%
|
56.74%
|
-
|
143.64%
|
68.36%
|
82.53%
|
88.88%
|
Dividend per Share
2 |
0.1597
|
0.1667
|
0.1600
|
0.1600
|
0.2000
|
0.1954
|
0.2233
|
0.3030
|
Announcement Date
|
3/22/20
|
4/19/21
|
4/22/22
|
4/21/23
|
4/17/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020 S1
|
2021 S1
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 S1
|
2022 Q3
|
2022 Q4
|
2022 S2
|
2023 Q1
|
2023 Q2
|
2023 S1
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 S1
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
11,309
|
-
|
5,707
|
5,479
|
4,750
|
10,228
|
5,717
|
5,330
|
11,047
|
5,492
|
5,676
|
11,168
|
5,845
|
5,806
|
5,998
|
6,246
|
12,193
|
6,587
|
6,704
|
6,088
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-
|
-408.2
|
1,366
|
1,033
|
2,399
|
1,253
|
460.1
|
1,713
|
1,344
|
1,226
|
2,570
|
1,371
|
968.6
|
1,636
|
1,241
|
2,807
|
1,415
|
1,338
|
1,285
|
-
|
Operating Margin
|
-
|
-
|
-7.15%
|
24.93%
|
21.75%
|
23.45%
|
21.92%
|
8.63%
|
15.51%
|
24.48%
|
21.6%
|
23.01%
|
23.46%
|
16.68%
|
27.28%
|
19.86%
|
23.02%
|
21.48%
|
19.96%
|
21.11%
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-462.5
|
-
|
986.4
|
2,352
|
1,182
|
434.5
|
1,617
|
-
|
1,188
|
2,512
|
1,300
|
854.7
|
-
|
1,435
|
2,952
|
1,583
|
1,573
|
-
|
-
|
Net income
1 |
2,662
|
2,668
|
323
|
-
|
882.4
|
2,119
|
1,054
|
732.9
|
-
|
-
|
1,069
|
2,308
|
1,166
|
828.7
|
1,369
|
1,309
|
2,697
|
1,422
|
1,422
|
-
|
-
|
Net margin
|
23.54%
|
-
|
5.66%
|
-
|
18.58%
|
20.72%
|
18.44%
|
13.75%
|
-
|
-
|
18.84%
|
20.67%
|
19.94%
|
14.27%
|
22.82%
|
20.95%
|
22.12%
|
21.58%
|
21.21%
|
-
|
-
|
EPS
2 |
-
|
-
|
0.0500
|
0.1900
|
0.1400
|
-
|
0.1700
|
0.1100
|
-
|
0.1900
|
0.1700
|
-
|
0.1900
|
0.1300
|
0.2100
|
0.2141
|
-
|
0.2284
|
0.2112
|
0.1900
|
-
|
Dividend per Share
2 |
-
|
-
|
0.1600
|
-
|
-
|
-
|
-
|
0.1600
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
0.0670
|
-
|
0.0670
|
0.0670
|
0.0811
|
0.0811
|
Announcement Date
|
7/31/20
|
8/19/21
|
4/22/22
|
4/22/22
|
8/19/22
|
8/19/22
|
10/28/22
|
4/21/23
|
4/21/23
|
4/21/23
|
8/18/23
|
8/18/23
|
10/25/23
|
4/17/24
|
4/17/24
|
-
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
5,044
|
10,805
|
13,631
|
13,850
|
20,746
|
23,358
|
27,485
|
31,257
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
3,257
|
2,881
|
2,570
|
-707
|
6,180
|
3,681
|
5,305
|
6,866
|
ROE (net income / shareholders' equity)
|
24%
|
22.5%
|
14%
|
10.9%
|
11%
|
12.2%
|
13.1%
|
14.2%
|
ROA (Net income/ Total Assets)
|
21.3%
|
20.3%
|
12.2%
|
9.57%
|
-
|
10.7%
|
11.6%
|
12.9%
|
Assets
1 |
24,959
|
31,144
|
36,996
|
40,811
|
-
|
50,520
|
55,649
|
60,033
|
Book Value Per Share
2 |
3.890
|
4.770
|
5.470
|
5.930
|
6.340
|
6.990
|
7.930
|
8.730
|
Cash Flow per Share
2 |
0.6000
|
0.5400
|
0.6600
|
0.2000
|
1.200
|
0.6600
|
0.9000
|
1.040
|
Capex
1 |
560
|
551
|
1,649
|
1,972
|
1,464
|
1,464
|
1,398
|
1,593
|
Capex / Sales
|
2.41%
|
1.99%
|
6.36%
|
9.27%
|
6.41%
|
5.57%
|
4.68%
|
4.59%
|
Announcement Date
|
3/22/20
|
4/19/21
|
4/22/22
|
4/21/23
|
4/17/24
|
-
|
-
|
-
|
Last Close Price
45.61
CNY Average target price
57.6
CNY Spread / Average Target +26.29% Consensus |
1st Jan change
|
Capi.
|
---|
| +0.84% | 40.02B | | +25.83% | 661B | | +27.00% | 566B | | -6.76% | 352B | | +20.34% | 332B | | +3.00% | 283B | | +13.09% | 231B | | +5.46% | 200B | | -9.61% | 195B | | -6.26% | 145B |
Other Pharmaceuticals
|